StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. META
5. SPY
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
STEMCELLS (NYSE: STEM) Delayed: 7.65 -0.41 (5.09%)
Previous Close $8.06    52 Week High $3.08 
Open $7.74    52 Week Low $0.21 
Day High $8.13    P/E N/A 
Day Low $7.64    EPS $-0.49 
Volume 53,231